Goldman Sachs Maintains Neutral on Medtronic, Lowers Price Target to $83

Benzinga Newsdesk www.benzinga.com Negative 74.4%

Neg 74.4% Neu 0% Pos 0%

Goldman Sachs analyst David Roman maintains Medtronic (NYSE:MDT) with a Neutral and lowers the price target from $84 to $83.